Danaher Corporation (DHR) is a global science and technology innovator with a market cap of $163 billion, offering professional, medical, research, and industrial products worldwide through its Biotechnology, Life Sciences, and Diagnostics segments.

As a large-cap stock valued at $10 billion, Danaher has seen a 10.6% decline from its 52-week high, with shares increasing 11.1% over the past three months but lagging behind the Health Care Select Sector SPDR Fund.

Despite underperforming in the past year, Danaher saw a 5.9% increase in shares after reporting better-than-expected Q3 2025 results, including revenue of $6.05 billion and a maintained full-year adjusted EPS outlook of $7.70 – $7.80.

Analysts remain bullish on Danaher stock, with a consensus rating of “Strong Buy” from 21 analysts and a mean price target of $251.68, reflecting a 9.1% premium to current levels.

Read more at Yahoo Finance: Is DHR Underperforming the Healthcare Sector?